ATE479676T1 - Als antikoagulanzien verwendbare phenylglycinamid-derivate - Google Patents

Als antikoagulanzien verwendbare phenylglycinamid-derivate

Info

Publication number
ATE479676T1
ATE479676T1 AT06717735T AT06717735T ATE479676T1 AT E479676 T1 ATE479676 T1 AT E479676T1 AT 06717735 T AT06717735 T AT 06717735T AT 06717735 T AT06717735 T AT 06717735T AT E479676 T1 ATE479676 T1 AT E479676T1
Authority
AT
Austria
Prior art keywords
anticoagulants
derivatives usable
phenylglycinamide
phenylglycinamide derivatives
usable
Prior art date
Application number
AT06717735T
Other languages
English (en)
Inventor
Xiaojun Zhang
Eldon Scott Priestley
Alexandra A Nirschl
Yan Zou
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE479676T1 publication Critical patent/ATE479676T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06717735T 2005-01-10 2006-01-09 Als antikoagulanzien verwendbare phenylglycinamid-derivate ATE479676T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64275105P 2005-01-10 2005-01-10
PCT/US2006/000571 WO2006076246A2 (en) 2005-01-10 2006-01-09 Phenylglycinamide derivatives useful as anticoagulants

Publications (1)

Publication Number Publication Date
ATE479676T1 true ATE479676T1 (de) 2010-09-15

Family

ID=36587246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717735T ATE479676T1 (de) 2005-01-10 2006-01-09 Als antikoagulanzien verwendbare phenylglycinamid-derivate

Country Status (9)

Country Link
US (1) US7622585B2 (de)
EP (1) EP1856096B1 (de)
AR (1) AR054321A1 (de)
AT (1) ATE479676T1 (de)
DE (1) DE602006016566D1 (de)
ES (1) ES2349428T3 (de)
PE (1) PE20061117A1 (de)
TW (1) TW200637843A (de)
WO (1) WO2006076246A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828152B1 (de) * 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclische verbindungen als inhibitoren von faktor viia
DE602006011752D1 (de) * 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
AR058380A1 (es) * 2005-12-23 2008-01-30 Bristol Myers Squibb Co Inhibidores del factor viia macrociclicos utiles como anticoagulantes
WO2007082131A1 (en) * 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
JP2009539873A (ja) 2006-06-08 2009-11-19 ブリストル−マイヤーズ スクイブ カンパニー 抗凝固剤として有用な第ＶＩＩａ因子インヒビターとしての２−アミノカルボニルフェニルアミノ−２−フェニルアセトアミド類
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
CN101631784A (zh) * 2006-12-20 2010-01-20 百时美施贵宝公司 用作抗凝血药的二环内酰胺凝血因子viia抑制剂
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
EP2149565A1 (de) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
JP5417860B2 (ja) * 2008-08-26 2014-02-19 住友化学株式会社 α−ヒドロキシエステル類の製造方法
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP3170813B1 (de) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazol-derivate als pi3-kinase-hemmer
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US9944643B2 (en) 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
EP3134408B1 (de) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. Faktor-xia-hemmer
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
AU2016344476B2 (en) 2015-10-29 2020-08-13 Merck Sharp & Dohme Llc Factor XIa inhibitors
EP3371162B1 (de) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Makrocyclische spirocarbamat-derivate als faktor-xia-inhibitoren, pharmazeutisch verträgliche zusammensetzungen und deren verwendung
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN112225647A (zh) * 2020-10-14 2021-01-15 河南中医药大学 一种合成5-溴-2-甲氧基苯酚的方法
CN117466714A (zh) * 2023-10-30 2024-01-30 中国科学技术大学 一种2,4-二氯-5-卤代苯酚的制备方法
CN118344240A (zh) * 2024-04-16 2024-07-16 中国科学技术大学 一种2,4-二氯-5-溴苯酚的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
FR2667864B2 (fr) 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
US5866542A (en) 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
AU6944696A (en) 1995-09-14 1997-04-01 Shionogi & Co., Ltd. Novel phenylacetic acid derivatives and medicinal composition containing the same
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
PT921116E (pt) 1997-12-04 2003-11-28 Hoffmann La Roche Derivados de n-(4-carbamimido-fenil)-glicinamida
AU2300699A (en) 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
HRP20010427A2 (en) 1998-12-14 2002-06-30 Hoffmann La Roche Phenylglycine derivatives
US6472393B1 (en) 1999-01-13 2002-10-29 Genentech, Inc. Serine protease inhibitors
WO2001044172A1 (en) 1999-12-15 2001-06-21 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
EP1254901A4 (de) 2000-01-26 2003-03-05 Ono Pharmaceutical Co Stickstoffhältige, 5-gliedrige, zyklische verbindungen und diese als wirkstoffe enthaltende medikamente
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
DE10027025A1 (de) 2000-05-31 2001-12-06 Merck Patent Gmbh Clycinamide
AU2001281059A1 (en) 2000-08-02 2002-02-13 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
NZ526003A (en) 2000-10-20 2005-09-30 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
ES2332090T3 (es) 2001-04-06 2010-01-26 Biocryst Pharmaceuticals, Inc. Compuestos biarilicos como inhibidores de serina proteasa.
DE10139060A1 (de) 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate
US6642386B2 (en) 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
DE10214832A1 (de) 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
US7122559B2 (en) 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
EP1594845A4 (de) 2003-02-11 2008-05-21 Bristol Myers Squibb Co Als serinproteaseinhibitoren geeignete benzolacetamidverbindungen
US20050107409A1 (en) 2003-03-10 2005-05-19 Boehringer Ingelheim International Gmbh Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions
DE10310278A1 (de) 2003-03-10 2004-09-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aromatische Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
EP1828152B1 (de) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclische verbindungen als inhibitoren von faktor viia
DE602006011752D1 (de) 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Also Published As

Publication number Publication date
US20060166997A1 (en) 2006-07-27
ES2349428T3 (es) 2011-01-03
WO2006076246A3 (en) 2006-09-28
PE20061117A1 (es) 2006-10-13
WO2006076246A2 (en) 2006-07-20
US7622585B2 (en) 2009-11-24
DE602006016566D1 (de) 2010-10-14
AR054321A1 (es) 2007-06-20
TW200637843A (en) 2006-11-01
EP1856096B1 (de) 2010-09-01
EP1856096A2 (de) 2007-11-21

Similar Documents

Publication Publication Date Title
ATE479676T1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE460417T1 (de) Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten
DK1928882T3 (da) (s)-n-methylnaltrexon
DK2194043T3 (da) Fremgangsmåder
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
FI20055649L (fi) Paikanmääritystekniikoita
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
DK1943406T3 (da) Byggeelement
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE549324T1 (de) Tetrahydrobenzoxazine
EP1934716A4 (de) Komponentenarchitektur
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
EP1916896A4 (de) Nichtsteroid-antiandrogene
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502006005207D1 (de) Bauteilen
DE502005005839D1 (de) Feldgeerät
EP1867636A4 (de) Pyridylmethylsulfonderivat
DE602006007832D1 (de) Benzotriazolderivate als cannabinoidrezeptorantagonisten
DE602006014973D1 (de) Neuartige cercosporamidderivate
DE502006001397D1 (de) Lagerbuchse
DE102005052834B8 (de) Punktschweißklebverbindung
DE502006001004D1 (de) Hydrolager

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties